A Phase 2a, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of AA4500 In the Treatment of Dupuytren's Disease Nodules

Trial Profile

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of AA4500 In the Treatment of Dupuytren's Disease Nodules

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Dupuytren's contracture
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Auxilium Pharmaceuticals
  • Most Recent Events

    • 30 Sep 2016 Primary endpoint has been met. (Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements), as reported in an Endo Pharmaceuticals media release.
    • 30 Sep 2016 According to an Endo Pharmaceuticals media release, new data evaluating the safety and efficacy of Collagenase-clostridium-histolyticum injection will be presented during a podium presentation at the annual meeting of the American Society for Surgery of the Hand (ASSH) 2016.
    • 30 Sep 2016 Results published in an Endo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top